Brief: Astellas Pharma Inc - U.S. FDA Approves Expanded Label For Astellas' Izervay(Avacincaptad Pegol Intravitreal Solution) For Geographic Atrophy
12/02/2025 23:32
Feb 13 (Reuters) - Astellas Pharma Inc 4503.T :
* ASTELLAS PHARMA INC: U.S. FDA APPROVES EXPANDED LABEL FOR ASTELLAS' IZERVAY(AVACINCAPTAD
PEGOL
INTRAVITREAL SOLUTION) FOR GEOGRAPHIC ATROPHY
Source text: ID:nTSnl8b9b9
Further company coverage: 4503.T
(Reporting by Tokyo Newsroom)
((+81345201189;))
Recent news on Astellas Pharma
See all newsFocus: Trump's push for the world's lowest drug prices hits snag with mid-sized companies
China detains two Japanese nationals suspected of smuggling banned goods (updated)
Brief: Astellas Pharma: Institutional Shareholder Services Has Issued A Report Recommending A Vote Against A Director Candidate
Health Rounds: Veracyte genomic test identifies breast cancer patients who can skip chemo
Advisory: Alert wrongly tagged to Gold Rain Enterprises withdrawn